PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 8, 20260 citationsOpen Access

Regorafeni̇b-Induced Hand–foot Ski̇n Reacti̇on: A Case Report

View Full Paper
GTGizem Keklik¹, Gül Merve Şen1, Meltem Türkmen1*

Key Result

Regorafenib is frequently implicated in causing hand-foot skin reaction, a dermatologic adverse effect characterized by painful erythematous lesions on the palms and soles.

Key Points

  • This report aims to describe the occurrence of hand-foot skin reactions associated with regorafenib.
  • Detailed observation of symptoms after initiation of regorafenib treatment.
  • Assessment of skin lesions on palms and soles.
  • Documentation of progression to blistering or plaques.
  • Hand-foot skin reaction developed shortly after starting regorafenib.
  • Lesions were initially erythematous and became painful.
  • In some cases, progression included blistering and hyperkeratotic plaques.

Structured PICO

I
Intervention
Regorafenib
O
Outcome
Hand-foot skin reaction (HFSR)safety

Regorafenib is a multikinase inhibitor that can induce hand-foot skin reaction.

Abstract

Hand–foot syndrome (HFS) and hand–foot skin reaction (HFSR) are well-recognized dermatologic adverse effects associated with several cytotoxic chemotherapeutic agents and molecularly targeted multikinase inhibitors (MKIs). HFSR typically occurs shortly after the initiation of MKIs and is characterized by painful erythematous lesions on the palms and soles, which may later progress to blistering or hyperkeratotic plaques. Regorafenib, sorafenib, dabrafenib, and cabozantinib are among the most frequently implicated agents.1-3

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gizem Keklik¹, Gül Merve Şen1, Meltem Türkmen1* (2026) studied this question. Regorafenib is frequently implicated in causing hand-foot skin reaction, a dermatologic adverse effect characterized by painful erythematous lesions on the palms and soles.

synapsesocial.com/papers/69d5f13674eaea4b11a7ac09https://doi.org/10.5281/zenodo.19435972
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study2026
  2. 2Sorafenib-induced hand-foot syndrome in a patient with desmoid fibromatosis2026
  3. 3Identification of Keratinocyte Cytoprotectants against Toxicity by the Multikinase Inhibitor Sorafenib Using Drug Repositioning2024 · 2 citations
  4. 4Hand-and-Foot Syndrome or Reaction: The Upper Hand of Clinical Morphology in a Patient Receiving Multiple Chemotherapy Agents2025
  5. 5Hand–foot skin reaction as a positive prognostic factor in vascular endothelial growth factor receptor‐tyrosine kinase inhibitor treatment2026